# Novartis

> Novartis is a Basel-based prescription-medicines company that discovers, develops, manufactures and sells patented therapies in cardiovascular, renal and metabolic disease, immunology, neuroscience and oncology. After spinning off Sandoz in 2023, it concentrated its capital and research on five drug-making platforms - chemistry, biotherapeutics, xRNA, radioligand therapy, and gene and cell therapy - while selling medicines through regulated healthcare systems in 118 countries.

- **Founded:** 1996
- **Headquarters:** Basel, Switzerland
- **Founders:** Ciba-Geigy (Merger predecessor), Sandoz (Merger predecessor)
- **Team size:** 75,267 full-time-equivalent employees at December 31, 2025.
- **Products:** Entresto, Cosentyx, Kisqali, Kesimpta, Pluvicto
- **Notable:** Created in 1996 through the merger of Ciba-Geigy and Sandoz, then one of the largest corporate mergers on record., Completed the Sandoz spin-off in October 2023, leaving Novartis focused on innovative medicines., Reported $54.532 billion in 2025 net sales and $17.596 billion in free cash flow.

## Products & services

- **Entresto** — A prescription medicine for heart failure and selected pediatric heart-failure patients; Novartis's largest brand by 2025 sales.
- **Cosentyx** — An IL-17A inhibitor used across several inflammatory conditions, including plaque psoriasis and psoriatic arthritis.
- **Kisqali** — A CDK4/6 inhibitor used in certain forms of hormone receptor-positive, HER2-negative breast cancer.
- **Kesimpta** — A self-administered anti-CD20 therapy for relapsing forms of multiple sclerosis.
- **Pluvicto** — A radioligand therapy that delivers targeted radiation to PSMA-positive prostate-cancer cells.
- **Leqvio** — A small interfering RNA therapy that lowers LDL cholesterol with an initial dose, another at three months, then twice-yearly maintenance dosing.
- **Fabhalta** — An oral factor B inhibitor targeting the alternative complement pathway, approved in multiple rare blood and kidney indications depending on market.
- **Scemblix** — A STAMP inhibitor for certain patients with Philadelphia chromosome-positive chronic myeloid leukemia.
- **Zolgensma and Itvisma** — Gene-replacement therapies designed to address the genetic root cause of spinal muscular atrophy for different eligible populations and markets.

## Achievements

- Created in 1996 through the merger of Ciba-Geigy and Sandoz, then one of the largest corporate mergers on record.
- Completed the Sandoz spin-off in October 2023, leaving Novartis focused on innovative medicines.
- Reported $54.532 billion in 2025 net sales and $17.596 billion in free cash flow.
- Reached approximately 304 million patients in 2025 across 118 countries where products were sold.
- Built a top-product portfolio led in 2025 by Entresto, Cosentyx, Kisqali, Kesimpta and Pluvicto.
- Established a radioligand-therapy franchise with Pluvicto and Lutathera, supported by specialized manufacturing capacity.
- Maintains an external research network of more than 300 academic and 100 industry alliances.
- Received FDA traditional approval for Fabhalta in primary IgA nephropathy in July 2026.
- Received European Commission approval for Itvisma for a broad spinal muscular atrophy population in July 2026.

## Latest updates

- **2026-07** — Second-quarter net sales increased 1% in constant currencies, led by priority brands including Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio; full-year guidance was reaffirmed.
- **2026-07** — The FDA converted Fabhalta's US accelerated approval in primary IgA nephropathy to traditional approval after two-year data showed slower kidney-function decline.
- **2026-07** — The European Commission approved Itvisma as a one-time gene-replacement therapy for eligible children age two and older, teenagers and adults with 5q spinal muscular atrophy.
- **2026-07** — Novartis agreed to acquire Myricx Bio to add an NMT-inhibitor antibody-drug-conjugate platform and two lead oncology assets.
- **2026-07** — Novartis marked 30 years since European approval of the Ciba-Geigy and Sandoz merger that created the company.
- **2026-02** — Full-year 2025 results showed net sales of $54.532 billion, up 8% in reported and constant currencies.

## Links

- Website: https://www.novartis.com
- LinkedIn: https://www.linkedin.com/company/novartis
- Twitter/X: https://x.com/novartis
- GitHub: https://github.com/Novartis
- YouTube: https://www.youtube.com/user/novartis
- Instagram: https://www.instagram.com/novartis
- Facebook: https://www.facebook.com/novartis

---

Profile page: https://yespress.io/novartis
Published by YesPress — https://yespress.io
Last updated: 2026-08-14